Revenue
2015
2016
2017
2018
2019
2020
2021
2022
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $881,705 | $3.9M | $36.1M | $4.8M | $2.4M | $1.9M | $648,382 | — | — |
| Research & development | $70.1M | $32.2M | $31.2M | $16.1M | $36.4M | $98.3M | $89.6M | $48.6M | $26.0M | $15.4M | $5.9M | $1.3M | $210,670 |
| Operating expenses | $85.3M | $48.7M | $45.1M | $39.8M | $56.9M | $126.7M | $113.2M | $61.6M | $35.0M | $21.9M | $9.5M | $2.6M | $557,276 |
| Operating income | −$85.3M | −$48.7M | −$45.1M | −$39.8M | −$56.0M | −$122.8M | −$77.1M | −$56.7M | −$32.6M | −$20.0M | −$8.9M | −$2.6M | −$557,276 |
| EBITDAderived | −$85.1M | −$48.1M | −$44.4M | −$39.1M | −$55.0M | −$121.7M | −$76.4M | −$56.3M | −$32.3M | −$19.9M | −$8.8M | — | — |
| Net income | −$78.5M | −$40.2M | −$44.6M | −$42.3M | −$45.6M | −$111.3M | −$71.5M | −$55.7M | −$32.4M | −$20.0M | −$8.9M | −$2.5M | −$602,350 |
| Basic EPSper diluted share | -$5.90 | -$3.68 | -$10.31 | -$10.15 | -$11.15 | -$1.42 | -$1.12 | -$0.98 | -$0.65 | -$0.49 | -$0.28 | -$0.13 | -$0.09 |
| Diluted EPSper diluted share | -$5.90 | -$3.68 | -$10.31 | -$10.15 | -$11.15 | -$1.42 | -$1.12 | -$0.98 | -$0.65 | -$0.49 | -$0.28 | -$0.13 | -$0.09 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 10, 2026Form 4 · 10b5-1 | Kung WinstonDirector | SellCommon Stock, par value $0.0001 per share | 2.0K | $7.91 | $16.0K | 12.1K |
| Jun 10, 2026Form 4 · 10b5-1 | Jenkins John KennethDirector | SellCommon Stock, par value $0.0001 per share | 4.8K | $7.91 | $38.0K | 3.8K |
| Jun 10, 2026Form 4 · 10b5-1 | Altmeyer AnneDirector | SellCommon Stock, par value $0.0001 per share | 2.4K | $7.91 | $19.1K | 7.6K |
| Jun 3, 2026Form 4 | Saxena Nishant CChief Business Officer | BuyCommon Stock, par value $0.0001 per share | 9.0K | $7.58 | $68.2K | 75.3K |
| Jun 2, 2026Form 4 | Saxena Nishant CChief Business Officer | BuyCommon Stock, par value $0.0001 per share | 4.5K | $7.33 | $33.0K | 66.3K |